Article
Multiple sclerosis-associated EBNA2 variants influence the response to peginterferon beta-1a therapy.
Journal of autoimmunity - 1 Mar 2026
Veroni Caterina, Carbone Fortunata, Ricci Daniela, Proietti Stefania, Romano Silvia, Buscarinu Maria Chiara, Rizzo Fabiana, Marrone Antonio, Micillo Teresa, Perna Francesco, Garziano Federica, Guerrera Gisella, Valentino Paola, Meloni Chiara, Bellucci Gianmarco, Bertolotto Antonio, Battistini Luca, Ristori Giovanni, Centonze Diego, Matarese Giuseppe, Coccia Eliana M, Salvetti Marco, Severa Martina, Mechelli Rosella
Abstract excerpt
BACKGROUND: Strong evidence links Epstein-Barr virus (EBV) infection to Multiple Sclerosis (MS). Peginterferon beta-1a (peg-IFN), currently the most used interferon formulation among first-line treatments in MS, displays immunomodulatory, anti-inflammatory, and antiviral properties and remains also an important therapeutic option in conditions such as pregnancy, lactation and aging patients. OBJECTIVES: In this...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
